Avalo Therapeutics, Inc. financial data

Symbol
AVTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
540 Gaither Road, Suite 400, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
Cerecor Inc. (to 8/18/2021)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 114 % +34%
Quick Ratio 0.07 % -49%
Debt-to-equity 1.53K % +31.8%
Return On Equity -503 % +65.1%
Return On Assets -29.2 % +74.4%
Operating Margin -15.5K % -993%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.7M shares +932%
Common Stock, Shares, Outstanding 10.5M shares +1206%
Entity Public Float 12.9M USD +169%
Common Stock, Value, Issued 10K USD +900%
Weighted Average Number of Shares Outstanding, Basic 4.43M shares +1494%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares +5435%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 441K USD -77.1%
General and Administrative Expense 17.2M USD +67.4%
Costs and Expenses 69M USD +136%
Operating Income (Loss) -68.5M USD -150%
Nonoperating Income (Expense) 33.5M USD -4131%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -35M USD -11.1%
Income Tax Expense (Benefit) 114K USD +714%
Net Income (Loss) Attributable to Parent -35.1M USD -11.4%
Earnings Per Share, Basic -7.94 USD/shares +93%
Earnings Per Share, Diluted -20.9 USD/shares +81.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 135M USD +1715%
Accounts Receivable, after Allowance for Credit Loss, Current 38K USD
Inventory, Net 0 USD -100%
Assets, Current 139M USD +1554%
Operating Lease, Right-of-Use Asset 741K USD -44.2%
Goodwill 10.5M USD 0%
Assets 151M USD +618%
Accounts Payable, Current 283K USD -36.5%
Employee-related Liabilities, Current 2.88M USD +397%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 6.96M USD +50.7%
Deferred Income Tax Liabilities, Net 270K USD +74.2%
Operating Lease, Liability, Noncurrent 350K USD -74.4%
Other Liabilities, Noncurrent 350K USD -74.4%
Liabilities 17.7M USD +29.3%
Retained Earnings (Accumulated Deficit) -370M USD -10.5%
Stockholders' Equity Attributable to Parent 133M USD +1721%
Liabilities and Equity 151M USD +618%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.2M USD +38.3%
Net Cash Provided by (Used in) Financing Activities 109M USD +690%
Net Cash Provided by (Used in) Investing Activities 356K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 10.5M shares +1206%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 103M USD +2784%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 135M USD +1685%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 65.7M USD +15.4%
Deferred Tax Assets, Gross 65.4M USD +15.2%
Operating Lease, Liability 918K USD -51.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -121M USD -1118%
Lessee, Operating Lease, Liability, to be Paid 1.01M USD -56.5%
Operating Lease, Liability, Current 568K USD +5.77%
Lessee, Operating Lease, Liability, to be Paid, Year Two 392K USD -28.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 558K USD +2.76%
Deferred Income Tax Expense (Benefit) 7K USD -12.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 95K USD -77.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 63K USD -88.7%
Deferred Tax Assets, Operating Loss Carryforwards 42.7M USD +14.5%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 201K USD -22.1%
Additional Paid in Capital 503M USD +47%
Amortization of Intangible Assets 0 USD -100%
Depreciation, Depletion and Amortization 34K USD +3.03%
Share-based Payment Arrangement, Expense 5.85M USD +68.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%